Analyst Rating
based on 31 analysts
38.71%
Buy
32.26%
Hold
29.03%
Sell
Based on 31 analysts offering long term price targets for Zydus Lifesciences Ltd. An average target of ₹1195.74
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd Share analysis
Zydus Lifesciences Ltd price forecast by 31 analysts
Upside of10.72%
High
₹1500
Target
₹1195.74
Low
₹816
Zydus Lifesciences Ltd target price ₹1195.74, a slight upside of 10.72% compared to current price of ₹1054.45. According to 31 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.13%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences Ltd EPS growth forecast
EPS estimate Q1, FY2026:24.17%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,042.1₹1,09552 Week's Low
52 Week's High
₹567.75₹1,324.3
| Returns % | |
| 1 Month Return | -8.86 % |
| 3 Month Return | + 0.6 % |
| 1 Year Return | + 72.86 % |
| Market Stats | |
| Previous Close | ₹1,079.95 |
| Open | ₹1,095.00 |
| Volume | 27.37L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,08,668.24Cr |
Key Statistics
| P/E Ratio | 26.02 |
| PEG Ratio | 1.57 |
| Market Cap | ₹1,08,668.24 Cr |
| P/B Ratio | 6.43 |
| EPS | 38.31 |
| Dividend Yield | 0.3 |
| Sector | Pharmaceuticals |
| ROE | 23.45 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,08,668.24 Cr | 70.73% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹16,459.31 Cr | 5.22% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹90,184.74 Cr | 30.78% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹59,038.98 Cr | 36.49% | 0.53 | NA | NA | |
| BUY | ₹47,286.31 Cr | 20% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Company Information
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Share Price: ₹1054.45 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹1,08,668.24Cr as of today
Revenue: ₹6,046.50Cr as on June 2024 (Q2 24)
Net Profit: ₹1,463.60Cr as on June 2024 (Q2 24)
Listing date: 27 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Zydus Lifesciences Ltd
Zydus Lifesciences Acquires Sterling Biotech's API Business - 17 Sep, 2024
Zydus Lifesciences has approved the acquisition of Sterling Biotech's fermentation-based API business for ₹84 crore. The deal is expected to enhance Zydus's strategic capabilities and is set for completion by December 31, 2024.
Zydus Faces FDA Warning Amid Licensing Agreement - 16 Sep, 2024
Zydus Lifesciences received a warning letter from the USFDA for manufacturing violations at its Gujarat plant. Simultaneously, it secured a licensing agreement for MRI contrast agents with Viwit Pharmaceuticals.
Zydus Faces FDA Warning Amid Licensing Agreement - 15 Sep, 2024
Zydus Lifesciences has signed a licensing agreement with Viwit Pharmaceuticals for US market injections while facing a USFDA warning for manufacturing lapses at its Jarod plant.
Zydus Lifesciences Partners with Viwit for MRI Agents - 13 Sep, 2024
Zydus Lifesciences Global FZE has entered an exclusive licensing and supply agreement with Viwit Pharmaceuticals for gadobutrol and gadoterate meglumine injections, targeting the US market. The total addressable market for these products is estimated at $237 million.
USFDA Issues Warning Letter to Zydus Lifesciences - 12 Sep, 2024
Zydus Lifesciences received a USFDA warning letter for its Jarod facility due to inadequate manufacturing practices, including cross-contamination and poor aseptic procedures. The FDA emphasized the need for corrective actions to avoid further regulatory consequences. Despite this, Zydus shares are up 1.25% and have risen 61% in 2024.
Zydus Receives Positive Analyst Rating and Clinical Progress - 11 Sep, 2024
Zydus Lifesciences announced the completion of a Phase II(a) study for Usnoflast in ALS patients, showing promising results. Jefferies also issued a buy rating with a ₹1,450 target, highlighting strong US market potential.
Zydus Completes Promising ALS Drug Trial - 10 Sep, 2024
Zydus Lifesciences successfully completed a Phase II(a) trial for Usnoflast, showing safety and improvements in ALS patients. The trial indicates potential benefits for neurodegenerative conditions.
Zydus Faces GST Demand of Rs 16.76 Crore - 09 Sep, 2024
Zydus Lifesciences has received a GST demand order of Rs 16.76 crore from the Goa Commissionerate, citing ineligible input tax credit claims from FY 2017-18 to 2019-20.
Zydus Lifesciences Reports Growth Amid GST Challenge - 08 Sep, 2024
Zydus Lifesciences has seen a 90% stock surge year-to-date, driven by strong revenue growth and FDA approvals. However, the company faces a Rs 16.76 crore GST demand, which it plans to appeal, asserting no material impact on operations.
Zydus Lifesciences Faces USFDA Warning Letter - 04 Sep, 2024
Zydus Lifesciences has received a warning letter from the USFDA concerning its injectable manufacturing facility in Jarod, citing violations of good manufacturing practices. The company plans to address the issues promptly.
Zydus Lifesciences Addresses FDA Warning Letter Concerns - 03 Sep, 2024
Zydus Lifesciences received a warning letter from the US FDA regarding its injectable facility in Jarod. The company assures that ongoing supply and financials remain unaffected, with remediation measures already in place.
Zydus Lifesciences Gains Approvals Amid Facility Warning - 30 Aug, 2024
Zydus Lifesciences has made significant moves, acquiring a stake in Sterling Biotech, receiving USFDA approval for Scopolamine transdermal system, but also facing a warning letter for its Jarod facility.
Zydus Lifesciences Upgraded by Jefferies - 29 Aug, 2024
Zydus Lifesciences shares rose following Jefferies' upgrade to a buy rating. The firm cites a strong US pipeline and improved growth prospects in India, though warns of risks from reliance on the US market.
Zydus Lifesciences Sees Strong Growth and FDA Approval - 28 Aug, 2024
Zydus Lifesciences reported a 31% rise in Q1FY25 net profit, received FDA approval for Amantadine capsules, and was upgraded to 'Buy' by Jefferies, highlighting strong US pipeline potential.
Zydus Lifesciences Receives USFDA Approval for Amantadine - 27 Aug, 2024
Zydus Lifesciences has secured USFDA approval for Amantadine extended-release capsules, enhancing its portfolio in Parkinson's treatment. The company is eligible for 180 days of exclusivity for the 68.5 mg dosage.
Zydus Lifesciences Faces Stock Drop After Acquisition - 26 Aug, 2024
Zydus Lifesciences announced a 50% stake acquisition in Sterling Biotech for Rs 550 crore, leading to a nearly 6% drop in shares amid analyst concerns over valuation and competition.
Zydus Acquires Stake in Sterling Biotech - 25 Aug, 2024
Zydus Lifesciences has signed an agreement to acquire a 50% stake in Sterling Biotech for Rs 550 crore. Citi maintains a Sell rating, citing competition risks impacting Zydus's sales and EBITDA.
Zydus Lifesciences Enters Fermentation-Based Protein Sector - 24 Aug, 2024
Zydus Lifesciences, through its subsidiary, has signed a Rs 550 crore deal to acquire a 50% stake in Sterling Biotech from Perfect Day Inc, marking its entry into the fermentation-based protein sector.
Zydus Forms Joint Venture for Animal-Free Protein - 23 Aug, 2024
Zydus Lifesciences announced the acquisition of a 50% stake in Sterling Biotech, creating a joint venture focused on manufacturing fermented animal-free protein for global markets.
Zydus Lifesciences Upgraded to BUY by Analysts - 21 Aug, 2024
Zydus Lifesciences received an upgrade to BUY from KR Choksey, with a target price of Rs 1,439, driven by strong revenue growth and improved EBITDA margins.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 6.71% to 7.24% in Jun 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.66% to 6.80% in Jun 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 789.6 Cr → 1.41K Cr (in ₹), with an average increase of 25.0% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 4.42K Cr → 6.27K Cr (in ₹), with an average increase of 10.7% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 44.9%
- NO EFFECT
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 78.3% return, outperforming this stock by 5.5%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Jun 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 7 days, ZYDUSLIFE stock has moved down by -3.6%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 5.72% to 5.59% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | ||
| Foreign Institutions | 5.59% | ||
| Mutual Funds | 7.24% | 7.81 | |
| Retail Investors | 6.8% | 2.06 | |
| Others | 5.4% |
Key Indicators
Zydus Lifesciences Ltd Valuation
Zydus Lifesciences Ltd in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (26.02x)
September 18, 2024
Industry (58.50x)
September 18, 2024
Highest (34.62x)
March 26, 2024
Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 30.64% since last year same period to ₹1,419.90Cr in the Q1 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 20.1% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.85%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Zydus Lifesciences Ltd shares.
Zydus Lifesciences Ltd (ZYDUSLIFE) share price today is ₹1054.45
Zydus Lifesciences Ltd is listed on NSE
Zydus Lifesciences Ltd is listed on BSE
- Today’s highest price of Zydus Lifesciences Ltd is ₹1095.
- Today’s lowest price of Zydus Lifesciences Ltd is ₹1042.1.
PE Ratio of Zydus Lifesciences Ltd is 26.02
PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share
Today’s traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 27.37L.
Today’s market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹108668.24Cr.
| Zydus Lifesciences Ltd(ZYDUSLIFE | Price |
|---|---|
52 Week High | ₹1324.3 |
52 Week Low | ₹567.75 |
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹1054.45. It is down -20.38% from its 52 Week High price of ₹1324.3
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹1054.45. It is up 85.72% from its 52 Week Low price of ₹567.75
| Zydus Lifesciences Ltd(ZYDUSLIFE | Returns |
|---|---|
1 Day Returns | -25.5% |
1 Month Returns | -8.86% |
3 Month Returns | 0.6% |
1 Year Returns | 72.86% |